Optimization of an Imidazo[1,2-<i>a</i>]pyridine Series to Afford Highly Selective Type I1/2 Dual Mer/Axl Kinase Inhibitors with <i>In Vivo</i> Efficacy.

导出原文传递

翻译打印收藏纠错

第一作者： William,McCoull

第一单位： Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K.

作者： William,McCoull ^[1] ; Scott,Boyd ^[1] ; Martin R,Brown ^[2] ; Muireann,Coen ^[3] ; Olga,Collingwood ^[1] ; Nichola L,Davies ^[1] ; Ann,Doherty ^[3] ; Gary,Fairley ^[1] ; Kristin,Goldberg ^[1] ; Elizabeth,Hardaker ^[1] ; Guang,He ^[4] ; Edward J,Hennessy ^[5] ; Philip,Hopcroft ^[2] ; George,Hodgson ^[2] ; Anne,Jackson ^[2] ; Xiefeng,Jiang ^[4] ; Ankur,Karmokar ^[6] ; Anne-Laure,Lainé ^[7] ; Nicola,Lindsay ^[1] ; Yumeng,Mao ^[1] ; Roshini,Markandu ^[1] ; Lindsay,McMurray ^[1] ; Neville,McLean ^[1] ; Lorraine,Mooney ^[6] ; Helen,Musgrove ^[6] ; J Willem M,Nissink ^[1] ; Alexander,Pflug ^[2] ; Venkatesh Pilla,Reddy ^[3] ; Philip B,Rawlins ^[2] ; Emma,Rivers ^[2] ; Marianne,Schimpl ^[2] ; Graham F,Smith ^[3] ; Sharon,Tentarelli ^[5] ; Jon,Travers ^[1] ; Robert I,Troup ^[1] ; Josephine,Walton ^[1] ; Cheng,Wang ^[4] ; Stephen,Wilkinson ^[1] ; Beth,Williamson ^[1] ; Jon,Winter-Holt ^[1] ; Dejian,Yang ^[4] ; Yuting,Zheng ^[4] ; Qianxiu,Zhu ^[4] ; Paul D,Smith ^[1]

作者单位： Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K. ^[1] Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, U.K. ^[2] Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge CB4 0WG, U.K. ^[3] Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, P. R. China. ^[4] Oncology R&D, AstraZeneca, Gatehouse Park, Waltham, Massachusetts 02451, United States. ^[5] Oncology R&D, AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K. ^[6] Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge CB4 0WG, U.K. ^[7]